<DOC>
	<DOC>NCT02910583</DOC>
	<brief_summary>This study is to determine the clinical minimum residual disease (MRD) response with the combination of ibrutinib plus venetoclax in subjects with treatment-naive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma</brief_summary>
	<brief_title>Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria (Hallek 2008), with active disease meeting at least 1 IWCLL criteria for requiring treatment. Measurable nodal disease by computed tomography (CT) Adequate hepatic, and renal function Adequate hematologic function absolute neutrophil count &gt;750/µL platelet count &gt;30,000 /μL hemoglobin &gt;8.0 g/dL Any prior therapy used for treatment of CLL/SLL Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for TLS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>